AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Growth_hormone

    Sermorelin (10mg)

    Subcutaneous injectionDaily, before bedtime10mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇺🇸 FDA (Discontinued)

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Approved by FDA only — not in all jurisdictions
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Available sizes:
    10mg
    2mg
    5mg
    15mg

    Research monograph

    See the full Sermorelin encyclopedia page with mechanism, evidence tier, related variants and research context.

    Open monograph
    Free Access

    How It Works

    Sermorelin binds to GHRH receptors in the pituitary gland, activating the pulsatile secretion of growth hormone and increasing IGF-1 levels.

    Quick Start

    • Typical dose: 200–300mcg subcutaneously, before bedtime
    • Frequency: Daily or 5 days/week
    • Storage: 2–8°C after reconstitution, use within 28 days
    Detailed Protocol Data

    Dosing Table — Sermorelin 10mg

    Educational only
    Vial Size— affects syringe units
    BAC Water4 mL
    Concentration2.50 mg/mL

    Route: Subcutaneous injection | Frequency: Daily, before bedtime

    WeekDoseUnits (per injection)
    1–2
    200mcg
    8 Units (0.08 mL)
    3–4
    250mcg
    10 Units (0.10 mL)
    5+
    300mcg
    12 Units (0.12 mL)

    Studies report administration before bedtime on an empty stomach. The 10mg vial provides ~33 doses of 300mcg.

    Related compounds

    Reconstitution Steps

    1. Clean the stoppers with an alcohol swab.
    2. Draw up 4mL of bacteriostatic water.
    3. Inject slowly down the side of the vial — do not shake.
    4. Gently swirl until fully dissolved.
    5. Store in the refrigerator (2–8°C).

    Protocol Overview

    • Sermorelin mimics the action of natural GHRH, stimulating the pituitary gland.
    • It maintains the natural negative feedback mechanism.
    • The 10mg vial is more cost-effective for long-term protocols.

    Dosing Protocol

    • Start with 200mcg/day and gradually increase to 300mcg.
    • Administer before bedtime on an empty stomach.
    • Cycle: 3–6 months on, 1 month off.
    • Break between cycles: After a cycle (3–6 months), a washout period of 4–8 weeks is recommended. This break prevents tolerance to the GHRH receptor.

    Washout & Cycle Restart

    When can I restart?

    After a cycle (3–6 months), a washout period of 4–8 weeks is recommended. This break prevents tolerance to the GHRH receptor.

    Minimum wait period: 4 weeks

    Storage Instructions

    • Lyophilized powder: room temperature or refrigerator.
    • Reconstituted solution: 2–8°C, use within 28 days.
    • Do not freeze after reconstitution.

    Important Notes

    • Avoid food for 2 hours before administration.
    • Consult a physician before use.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Increased natural GH production
    • Improved sleep quality
    • Enhanced muscle growth
    • Reduced body fat

    Potential Side Effects:

    • Injection site irritation
    • Transient headache
    • Flushing

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🎗️ Cancer Markers
    🟡 Moderate / Theoretical

    Theoretical risk (IGF-1 elevation)

    As a GHRH analogue, increases GH/IGF-1. Same theoretical concern as exogenous GH, but to a lesser degree due to physiological regulation.

    📄 FDA Label — Geref® (withdrawn)

    References

    1. Sermorelin: GHRH Analog — Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
      View Source
    2. GHRH and GH secretion — Corpas E, et al. Endocr Rev. 1993;14(1):20-39.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Approved
    FDA Status
    1
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇺🇸
    FDA
    Approved (discontinued)

    Geref® · GH deficiency (children) (1997)

    FDA approved (withdrawn 2008)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    0 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu